Active Investments

Aclaris Therapeutics
Aclaris, started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies.
Aerie Pharmaceuticals
Aerie Pharmaceuticals is a privately held, clinical-stage biotechnology company dedicated to the discovery and development of novel treatments for glaucoma. The Company is located in Bridgewater, NJ and Research Triangle Park, NC.
Alimera Sciences
Alimera Sciences, Inc., based in Alpharetta, GA, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera is focused on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, is an intravitreal implant containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease.
Alvine
Alvine is a Phase 2 clinical company developing biologics to target autoimmune/inflammatory diseases. The company’s lead product candidate, ALV003, is a mixture of two proteases engineered to degrade gluten. Gluten is the difficult to digest protein found in wheat, rye, and barley that triggers celiac disease in genetically susceptible individuals.
Amarin
Amarin is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease. Amarin’s lead candidate, AMR101, is currently being launch after approval. The company’s cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease. (Nasdaq: AMRN)
Anthera Pharmaceuticals
Anthera is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. (Nasdaq: ANTH)
Ascenta Therapeutics
Ascenta is a clinical stage biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer. Ascenta’s current focus is a portfolio of novel, orally-active, small molecule drugs that restore the natural potential for cancer cells to undergo cell death (apoptosis). Ascenta’s lead drug candidate, AT-101) is currently in Phase 2b clinical trials.
Auris Medical
Auris Medical is a Swiss biotechnology company developing specific pharmaceutical compounds for the prevention or treatment of inner ear disorders, an area of great unmet medical need. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. The company has completed successful Phase IIb clinical trials in both tinnitus and acute hearing loss.
Catalyst Biosciences
Catalyst is a drug discovery and development company that is creating novel catalytic biopharmaceutical products based on engineered human proteases. The Company is developing proteases for the treatment of a broad range of diseases with a strong focus on hemostasis and inflammation. Catalyst is developing both natural and engineered human proteases "Alterase Therapeutics" to treat major diseases.
Cebix
Cebix is a biopharmaceutical company focused on the development of chronic replacement therapy based on human proinsulin C-peptide for the treatment of type 1 diabetic neuropathy. The company has recently developed a once weekly dosage form which it is currently advancing into clinical trials. Cebix has met with the FDA and reached agreement with the Agency on its development plans in diabetic neuropathy.
Civitas Therapeutics
Civitas is a privately held biopharmaceutical company focused on developing and commercializing transformative therapeutics using its proprietary ARCUS™ technology, with an initial focus on treating OFF episodes in patients with Parkinson’s disease.
Coherus Biosciences
Coherus Biosciences is a biosimilar platform company that acquired Intekrin in Q1 2014. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases.The Company has built a capital efficient infrastructure capable of taking products from cell lines to approved labels.
Durata Therapeutics
Durata is a biopharmaceutical company addressing the growing need for new antibiotics to treat infectious diseases. Durata’s lead product candidate, dalbavancin, is in late-stage clinical development, and the company also has two antibiotic programs in earlier-stage, preclinical research.
First Aid Shot Therapy
Based in Burlingame, California, privately held First Aid Shot Therapy(R), Inc. is focused on the development and commercialization of a comprehensive portfolio of OTC pharmaceutical products in liquid 'shot' (40ml / 1.35oz.) format. The F.A.S.T. team is comprised of consumer product executives that have been responsible for the launch and commercial success of products such as VitaminWater and Pretzel Crisps. F.A.S.T.'s products are formulated by the Company's proprietary research and development organization, F.A.S.T. Labs(tm).
Histogenics
Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. Histogenics’ flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility.
Hyperion Therapeutics
Hyperion (NADSAQ: HPTX) is a pharmaceutical company focused on the development of treatments that address critical unmet needs in the areas of gastroenterology and hepatology. Hyperion aims to build its portfolio of products through partnership and in-licensing. Hyperion is currently focused on the development of one compound, glycerol phenybutyrate (HPN-100), for both urea cycle disorders (UCD) and hepatic encephalopathy (HE). The compound is currently in approved and in commercial stage for UCD and in Phase 2 studies for HE.
Innocoll
Innocoll is a global, commercial-stage, specialty pharmaceutical company. Innocoll develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies.
KaloBios
KaloBios is a monoclonal antibody company using its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. The company’s multiple programs have completed multiple Phase 1 or 2 clinical trials for Pseudomonas aeruginosa infections, cystic fibrosis patients, intensive care patients on a ventilator, inflammatory conditions and hematologic malignancies. (NASDAQ:KBIO)
Marinus Pharmaceuticals
Marinus is a specialty pharmaceutical company dedicated to the reformulation, development, and commercialization of novel drugs to treat serious neurological, psychiatric, and pain disorders. The company’s lead product is a first-in-class therapy for epilepsy.
Mirna Therapeutics
Mirna is harnessing the power of tumor suppressor microRNAs (miRNAs) to kill cancer cells by regaining control over multiple oncogenic pathways. Mirna’s miRNA \"mimic pipeline\" has broad therapeutic utility in solid and hematologic cancers as well as other therapeutic areas, and provides multiple opportunities for partnering and licensing.
NuCana
NuCana is a clinical stage biopharmaceutical company developing and commercialising novel anti-cancer medicines. With its next generation of anti-cancer agents (nucleotide analogues), NuCana is setting new benchmarks for innovative treatments. NuCana is transforming cancer agents (nucleoside analogues) into better and safer medicines that overcome key resistance mechanisms.
ObsEva
ObsEva is a Swiss-based, speciality biopharmaceutical company dedicated to the development of innovative drugs for women’s reproductive medicine. ObsEva’s main focus is on therapies for preterm labour.
Ocera
Ocera is a biopharmaceutical company focused on the licensing, development and commercialization of proprietary compounds to treat a broad range of gastrointestinal and liver diseases. Ocera is pursuing the development of AST-120 in Crohn's disease and other gastrointestinal and liver diseases including pouchitis, hepatic encephalopathy, irritable bowel syndrome and proton pump inhibitor-resistant gastroesophageal reflux disease.
Ophthotech Corporation
Ophthotech is a biopharmaceutical company specializing in the development of novel therapeutics to treat diseases of the eye. The company’s most advanced product candidate is Fovista™ anti-PDGF therapy, which it is developing for use in combination with anti-VEGF drugs that represent the standard of care for the treatment of wet age-related macular degeneration.
Principia Biopharma
Principia Biopharma is a privately-held biopharmaceutical company focused on discovering and developing first-in-class small molecule drugs within the fields of autoimmune disease and oncology that are potent, safe and have antibody-like specificity for their targets.
Prothena Corporation
Prothena Corporation plc (Nasdaq: PRTA) is a clinical-stage biotechnology company that is advancing and developing novel antibodies for broad range of diseases involving protein misfolding or cell adhesion. The company’s lead program is targeting orphan disease amyloidosis.
Salveo Specialty Pharmacy
Salveo, a private company headquartered in Saint Petersburg, FL, was formed to create a leading specialty pharmacy organization serving patients and customers across the country. Salveo acquires, integrates and grows select specialty pharmacy organizations that share its philosophy of providing superior customer service and clinical patient care to the chronically ill population.
Spark Therapeutics
Spark Therapeutics is a privately held biotech company focused on developing curative, one-time gene therapy products with the potential to transform the lives of patients and re-imagine the treatment of debilitating diseases. Spark's lead gene therapy candidate, for RPE65-related blindness, is currently in Phase 3 clinical trials. www.sparktx.com.
TESARO
TESARO is a oncology-focused biopharmaceutical company focused on improving the lives of cancer patients by developing safer and more effective therapeutics and supportive care products. TESARO was co-founded by former executives of MGI Pharma, an oncology company that was acquired in 2008 for $3.9B. (NASDAQ:TSRO)
Versartis, Inc.
Versartis, Inc. is a biotechnology company developing therapeutics for the treatment of endocrine disorders. The company’s lead product candidate is VRS-317, a novel long-acting form of human growth hormone. New compounds developed by Versartis using the XTEN technology are expected to provide improved therapeutic outcomes such as enhanced efficacy/compliance, fewer side effects, prolonged half-life (up to monthly dosing), as well as low-cost production and enhanced stability.
ZS Pharma
ZS Pharma is a privately held specialty pharmaceutical company focused on the treatment of kidney and liver diseases. ZS Pharma’s lead compound (ZS-9) is targeting hyperkalemia, a life-threatening metabolic condition characterized by an abnormally high serum concentration of potassium, and is currently in Phase 3 trials. ZS Pharma is headquartered in Coppell, Texas.